- Home
- AIM vs IBO Comparison
AIM vs IBO Comparison
Compare AIM & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- IBO
- Stock Information
- Founded
- AIM 1966
- IBO 2018
- Country
- AIM United States
- IBO United States
- Employees
- AIM N/A
- IBO N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- IBO
- Sector
- AIM Health Care
- IBO
- Exchange
- AIM Nasdaq
- IBO NYSE
- Market Cap
- AIM 15.9M
- IBO 17.9M
- IPO Year
- AIM N/A
- IBO 2024
- Fundamental
- Price
- AIM $0.21
- IBO $1.56
- Analyst Decision
- AIM Strong Buy
- IBO
- Analyst Count
- AIM 2
- IBO 0
- Target Price
- AIM $2.75
- IBO N/A
- AVG Volume (30 Days)
- AIM 672.1K
- IBO 31.8K
- Earning Date
- AIM 11-15-2024
- IBO 02-23-2025
- Dividend Yield
- AIM N/A
- IBO N/A
- EPS Growth
- AIM N/A
- IBO N/A
- EPS
- AIM N/A
- IBO 0.01
- Revenue
- AIM $190,000.00
- IBO N/A
- Revenue This Year
- AIM N/A
- IBO N/A
- Revenue Next Year
- AIM $1,693.10
- IBO N/A
- P/E Ratio
- AIM N/A
- IBO $129.11
- Revenue Growth
- AIM N/A
- IBO N/A
- 52 Week Low
- AIM $0.16
- IBO $1.16
- 52 Week High
- AIM $0.62
- IBO $3.25
- Technical
- Relative Strength Index (RSI)
- AIM 50.86
- IBO N/A
- Support Level
- AIM $0.19
- IBO N/A
- Resistance Level
- AIM $0.23
- IBO N/A
- Average True Range (ATR)
- AIM 0.02
- IBO 0.00
- MACD
- AIM -0.00
- IBO 0.00
- Stochastic Oscillator
- AIM 48.29
- IBO 0.00
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.